CH678490A5 - - Google Patents
Download PDFInfo
- Publication number
- CH678490A5 CH678490A5 CH4684/88A CH468488A CH678490A5 CH 678490 A5 CH678490 A5 CH 678490A5 CH 4684/88 A CH4684/88 A CH 4684/88A CH 468488 A CH468488 A CH 468488A CH 678490 A5 CH678490 A5 CH 678490A5
- Authority
- CH
- Switzerland
- Prior art keywords
- medicament according
- hydroxylysine
- medicament
- acid addition
- dimethylaminoethanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Description
CH678 490A5 CH678 490A5
Beschreibung description
Die Erfindung betrifft ein Arzneimittel, das als Wirksubstanz mindestens ein Isomeres des Hydroxyly-sins oder Lysins oder deren pharmazeutisch annehmbare Abkömmlinge, gegebenenfalls zusammen mit üblichen Trägern und/oder Hilfsmitteln enthält. Dabei ist zu beachten, dass das Isomere des Hydroxyly-sins oder Lysins in der L- oder D-Konfiguration vorliegen kann, wobei die L-Konfiguration bevorzugt ist, dass die Hydroxylgruppe sich von beta bis delta an verschiedenen Stellen der Kohlenstoffkette befinden kann, wobei die delta-Position bevorzugt ist und bezüglich der stereoisomeren Stellung der Hydroxylgruppe an einem asymmetrischen Kohlenstoffatom beide Isomere pharmazeutisch von Bedeutung sind. The invention relates to a medicament which contains at least one isomer of hydroxylysine or lysine or its pharmaceutically acceptable derivatives, optionally together with conventional carriers and / or auxiliaries, as the active substance. It should be noted here that the isomer of hydroxylysine or lysine can be in the L or D configuration, the L configuration being preferred so that the hydroxyl group can be located at various points in the carbon chain from beta to delta, where the delta position is preferred and both isomers are pharmaceutically important with regard to the stereoisomeric position of the hydroxyl group on an asymmetric carbon atom.
Die Wirkung dieser Arzneimittel kann durch die Zugabe von N-Methyl-aminoäthanol und/oder N-Di-methyl-aminoäthanol, z.B. in Form ihrer Säureadditionssalze gesteigert werden. The effect of these drugs can be increased by the addition of N-methylaminoethanol and / or N-dimethylaminoethanol, e.g. be increased in the form of their acid addition salts.
Die Strukturformeln dieser an sich bekannten Verbindungen werden hier nur der Vollständigkeit halberwiedergegeben. The structural formulas of these known compounds are only given here for the sake of completeness.
CH 678 490 A5 CH 678 490 A5
25 25th
30 30th
35 35
HOOC OH HOOC OH
i I i I
H-C-CH2-CH2-C-CH2"NH2 H-C-CH2-CH2-C-CH2 "NH2
* 1 * 1
H„N H H "N H
10 2 10 2
15 15
HOOC H HOOC H
i ! i!
20 H-C-CH2-CH2-C-CH2-NH2 20 H-C-CH2-CH2-C-CH2-NH2
I I.
H2N OH H2N OH
HOOC i HOOC i
HC-CH2-CH2-CH2-CH2-NH2 HC-CH2-CH2-CH2-CH2-NH2
40 H2N 40 H2N
45 H 45 h
50 50
55 55
+ +
(H3C-N-CH2"CH20H) (H3C-N-CH2 "CH20H)
N N
CH3 CH3
x- x-
i i
60 (H-N-CH2-CH2OH) x- 60 (H-N-CH2-CH2OH) x-
CH-, CH-,
65 65
3 3rd
5 5
"10 "10
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
50 50
55 55
60 60
CH 678 490 A5 CH 678 490 A5
Die genannten Verbindungen sind als solche bekannt und können nach an sich bekannten Verfahren hergestellt werden. The compounds mentioned are known as such and can be prepared by processes known per se.
Die erfindungsgemässen Arzneimittel können die Isomere des Hydroxylysins oder Lysins auch in Form von pharmazeutisch verträglichen Abkömmlingen enthalten, besonders solche, die im Körper in die freie Form der Derivate übergehen. Dazu gehören insbesondere Alkalisalze, Erdalkalisalze, Säureadditionssatze, Ester, Amide und Äther von Hydroxylysin oder Lysin und deren N-alkyl-Derivate sowie Oli-go- oder Polypeptide davon. The medicaments according to the invention can also contain the isomers of hydroxylysine or lysine in the form of pharmaceutically acceptable derivatives, especially those which are converted into the free form of the derivatives in the body. These include, in particular, alkali metal salts, alkaline earth metal salts, acid addition sets, esters, amides and ethers of hydroxylysine or lysine and their N-alkyl derivatives as well as oligo-go or polypeptides thereof.
Die erfindungsgemässen Arzneimittel dienen der Behandlung der nachfolgend aufgeführten Erkrankungen, sei es durch ihre alleinige Gäbe oder zur Unterstützung herkömmlicher Therapie. Die herkömmliche Therapie ist in vielen Fällen unbefriedigend, was schon daraus hervorgeht, dass in einer nicht kleinen Zahl von Fällen operative Eingriffe heute noch unumgänglich sind. The medicaments according to the invention are used to treat the diseases listed below, be it through their sole administration or to support conventional therapy. Conventional therapy is unsatisfactory in many cases, which is clear from the fact that surgical interventions are still unavoidable in a small number of cases.
Anwendungsgebiete der erfindungsgemässen Arzneimittel: Areas of application of the medicaments according to the invention:
1. Venenerkrankungen: Hierzu gehören vor allem Erweiterungen und entzündliche Veränderungen der Venen sowie Varicocoelen und Hämorrhoiden, ausserdem Hirnsinuserkrankungen und verwandte Krankheitsbilder. 1. Venous disorders: These primarily include dilatation and inflammatory changes in the veins as well as varicocoeles and hemorrhoids, as well as brain sinus disorders and related clinical pictures.
2. Herzerkrankungen: Vor allem Endocarditis und Folgen sowie Myocarditis und Folgen, wozu bei letzteren vor allem Herzrhythmusstörungen zu nennen sind. 2. Heart diseases: Above all endocarditis and consequences as well as myocarditis and consequences, for which the cardiac arrhythmias are particularly noteworthy.
3. Scharlach, Rheumatisches Fieber, Septische Gelenkerkrankungen, Erysipel Impetigo usw. 3. Scarlet fever, rheumatic fever, septic joint diseases, erysipelas impetigo etc.
4. Prostatitis und Adnexitis. 4. Prostatitis and adnexitis.
5. Analfissuren. 5. Anal fissures.
6. Zahncaries. 6. Dental caries.
7. Neurologische Erkrankungen, insbesondere solche, die mit Störungen der Motorik und Sensibilität einhergehen. 7. Neurological diseases, especially those associated with motor disorders and sensitivity disorders.
8. Hernien. 8. Hernias.
Das Wirkprinzip in allen obengenannten Fällen liegt in einer durch die erfindungsgemässen Arzneimit-tef bewirkten Stärkung von intra- und extrazellulären.Fasersystemen. The principle of action in all the above-mentioned cases lies in the strengthening of intra- and extracellular fiber systems brought about by the medicament according to the invention.
Die erfindungsgemässen Arzneimittel werden in grundsätzlich gleicher Weise verabreicht wie die gewöhnlichen Aminosäuren, also bevorzugt peroral oder intravenös, bzw. zentralintravenös. Auch die Zufuhrin Tabletten, Dragées, Injektions- und Infusionslösungen ist die gleiche. The medicaments according to the invention are administered in basically the same way as the usual amino acids, that is to say preferably orally or intravenously or centrally intravenously. The supply of tablets, dragees, injection and infusion solutions is the same.
Bei oberflächlichen gut zugänglichen Krankheitsherden kommt auch die örtliche Anwendung als Lösung, oder Puder, oder Salbe, oder dergleichen in Betracht. In the case of easily accessible foci of disease, topical application as a solution, or powder, or ointment, or the like, also comes into consideration.
Da es sich um untoxische Verbindungen handelt, kann sich die Dosierung in einem weiten Bereich bewegen, wobei man die übliche therapeutische Aminosäure-Dosierung mit 0,01 bis 0,1 g pro kg und Substanz auch hier zu Grunde legen kann.- Since these are non-toxic compounds, the dosage can vary within a wide range, whereby the usual therapeutic amino acid dosage of 0.01 to 0.1 g per kg and substance can also be used as a basis.
Die für alle Aminosäuren geltenden Kontraindikationen sind auch hier zu beachten. The contraindications that apply to all amino acids must also be observed here.
Die pharmazeutische Herstellung und Verarbeitung erfolgt in allgemein üblicher Weise und berücksichtigt die gesetzlichen Bestimmungen in Hinsicht auf Substanzreinheit, Sterilität, Pyrogenfreiheit usw. The pharmaceutical production and processing takes place in a generally customary manner and takes into account the legal provisions with regard to substance purity, sterility, freedom from pyrogens, etc.
Claims (6)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3744542A DE3744542B4 (en) | 1987-12-30 | 1987-12-30 | Pharmaceutical use of L-δ-hydroxylysine |
Publications (1)
Publication Number | Publication Date |
---|---|
CH678490A5 true CH678490A5 (en) | 1991-09-30 |
Family
ID=6343857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH4684/88A CH678490A5 (en) | 1987-12-30 | 1988-12-21 |
Country Status (3)
Country | Link |
---|---|
CH (1) | CH678490A5 (en) |
DE (1) | DE3744542B4 (en) |
GB (1) | GB2226759A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3912477A1 (en) * | 1989-04-15 | 1990-10-18 | Mueller Robert Dr | OUTSTANDING PRAEPARATE AND ITS USE |
IT1407715B1 (en) * | 2010-06-18 | 2014-04-30 | Alphrema Srl | COMPOSITIONS FOR TOPICAL USE FOR PROPHYLAXIS AND HYGIENIC TREATMENT OF SOME PROBLEMS OF ANO-RECTAL PATHOLOGY, LIKE HEMORROIDES, RAGADI, ASCESSES AND FISTULAS. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6588M (en) * | 1967-10-11 | 1968-12-30 | ||
GB1219869A (en) * | 1968-07-24 | 1971-01-20 | Farmaceutici Italia | Stabilized estrogen sulphate salts |
GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
BE789856A (en) * | 1971-10-13 | 1973-02-01 | Tixier Georges | MEDICINAL PRODUCT BASED ON LYSINE DERIVATIVES, WHICH MAY STIMULATE DIFFERENT METABOLISMS, IN PARTICULAR LEUKOCYTE GENESIS |
JPS60243028A (en) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | Solubilization of interferon |
FR2587900B1 (en) * | 1985-10-01 | 1988-10-07 | Morelle Jean | BASIC FATTY-AMINO ACID ASSOCIATIONS WITH EMOLLIENT, EMULSIFIING AND ANTIOXIDANT PROPERTIES FOR COSMETICS, DERMATOLOGY AND FOOD |
DE3728852C2 (en) * | 1987-08-28 | 2003-06-18 | Wilhelm Hoerrmann | Medicines for tumor therapy |
-
1987
- 1987-12-30 DE DE3744542A patent/DE3744542B4/en not_active Expired - Fee Related
-
1988
- 1988-12-21 CH CH4684/88A patent/CH678490A5/de not_active IP Right Cessation
-
1989
- 1989-01-04 GB GB8900048A patent/GB2226759A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB8900048D0 (en) | 1989-03-01 |
GB2226759A (en) | 1990-07-11 |
DE3744542B4 (en) | 2004-06-03 |
DE3744542A1 (en) | 1989-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69822665T2 (en) | USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES | |
DE2817358C2 (en) | ||
DE69732049T2 (en) | PHARMACEUTICAL PREPARATIONS, CONTAINING SALTS OF HYALURONIC ACID AND LOCAL ANESTHETICS | |
DE2911670A1 (en) | MEDICINES FOR THE THERAPEUTIC TREATMENT OF PERIPHERAL VASCULAR DISEASES | |
DE2903558A1 (en) | THERAPEUTIC METHOD OF TREATMENT OF HYPERLIPOPROTEINEMIA AND HYPERLIPIDAEMIA, AND MEDICINAL PRODUCTS FOR ITS PERFORMANCE | |
DE2903579A1 (en) | USE OF ACETYL CARNITINE AND OTHER ACYLDER DERIVATIVES OF CARNITINE FOR THE TREATMENT OF HYPERLIPOPROTEINEMIC AND HYPERLIMPIDAEMIA AND MEDICINAL PRODUCTS | |
DE3235093A1 (en) | ANTIPARKINSON AGENTS | |
EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
EP0752246A2 (en) | Kappa opiate agonists for inflammatory gut diseases | |
EP0530446A2 (en) | Use of sulfur containing carboxylic acids for combatting pathophysiologic excitatory disorders and related diseases as well as allergic diseases and their preparation as medicament | |
DE3726945A1 (en) | L-Carnitine derivatives of valproic acid and pharmaceuticals containing these | |
CH667591A5 (en) | MEDICATIONS CONTAINING HYDROXYPROLINE. | |
DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
DE2820794C2 (en) | Salts of (-Hcis) -l ^ -epoxypropylphosphonic acid, process for their preparation and pharmaceutical preparation containing them | |
DE2528609A1 (en) | DERIVATIVES OF APOVINCAMIC ACIDS | |
CH678490A5 (en) | ||
DE3525390C2 (en) | ||
DE3202561A1 (en) | Lysine salts of [(1-benzyl-1H-indazol-3-yl)oxy]acetic acid, process for their preparation and pharmaceuticals containing these | |
DE2335729A1 (en) | VINCANOL SALT, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS ACTIVE SUBSTANCES | |
DE3011274A1 (en) | SYNERGISTIC RADIATION PROTECTIVE PHARMACEUTICAL PREPARATIONS AND THEIR PRODUCTION | |
EP0223850B1 (en) | Medicines which contain derivatives of proline or hydroxyproline | |
DE2131679A1 (en) | 3,4,5-trimethoxybenzamidocarboxylic acids and their salts and medicinal preparations | |
DE69937574T2 (en) | USE OF THE PHARMACEUTICAL PREPARATION "HISTOCHROME" FOR THE TREATMENT OF ACUTE HERZINFARKTS AND ISCHEMIC ILLNESSES | |
DE2633891C2 (en) | Tris (hydroxymethyl) aminomethane salt of 2- (5-benzoylthienyl) -α-methyl acetic acid, process for its preparation and pharmaceutical compositions containing it | |
DE3844046A1 (en) | Pharmaceutical compositions which contain isomers of hydroxylysine or lysine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |